Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus

    NEXT STORY
    HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry
    PREV STORY
    BARDA Initiates the Procurement of NexoBrid for Emergency Response
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    R1 RCM Reports Second Quarter 2018 Results

    CHICAGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider ...

    author_avatar
    NASDAQ Market News

    NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting

    AMES, Iowa, June 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced ...

    author_avatar
    NASDAQ Market News

    FIT Biotech Oy: Positive results from gene therapy collaboration with Avacta

    FIT Biotech Oy  Company release 22.5.2018 at 9.30 EET Positive results from gene therapy ...

    author_avatar
    NASDAQ Market News